REVIEW

Systematic Review of Light-Based Treatments for Hidradenitis Suppurativa

T. Gracia Cazaña, a,b,* L.V. Berdín Díaz, b,* J.I. Martín Sánchez, c I. Querol Nasarre, b Y. Gilaberte d

a Unidad de Dermatología, Hospital de Barbastro, Barbastro, Huesca, Spain  
b Departamento de Medicina, Psiquiatría y Dermatología, Facultad de Medicina, Universidad de Zaragoza, Zaragoza, Spain  
c Decisiones Basadas en la Evidencia, Instituto Aragonés de Ciencias de la Salud, Zaragoza, Spain  
d Servicio de Dermatología, Hospital Universitario Miguel Servet, IIS Aragón, Zaragoza, Spain

Received 17 March 2019; accepted 22 April 2019  
Available online 14 February 2020

Abstract  
Treatment options for hidradenitis suppurativa include light-based therapy. This systematic review aimed to update our understanding of the efficacy, effectiveness and safety of these treatments for hidradenitis suppurativa by evaluating the literature published since the 2015 Cochrane review on this topic. We conducted an electronic search of the following databases: MEDLINE, EMBASE, University of York Centre for Reviews and Dissemination database, Cochrane Database of Systematic Reviews, Cochrane Skin Group Specialised Skin Register, University of Nottingham’s Centre of Evidence Based Dermatology database, and TESEO. The systematic review included 6 case series, 3 systematic reviews, and 2 clinical trials on the use of conventional and intralesional photodynamic therapy, intense pulsed light therapy, and Nd:YAG, carbon dioxide, and diode laser therapy for hidradenitis suppurativa in 248 patients.  
© 2019 AEDV. Published by Elsevier España, S.L.U. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

PALABRAS CLAVE  
Hidradenitis supurativa;  
Terapia fotodinámica;  
Láser;  
Luz intensa pulsada

Revisión sistemática de las terapias con luz en el tratamiento de la hidradenitis supurativa

Resumen  
La terapia con luz es una alternativa en el tratamiento de la hidradenitis supurativa (HS). El objetivo fue evaluar la eficacia, efectividad y seguridad de las distintas modalidades de terapia con luz en la HS, mediante una revisión sistemática actualizando la realizada en 2015 procedente de Cochrane Library. Se identificaron los estudios mediante una búsqueda electrónica en las bases de datos: MEDLINE, EMBASE, Universidad de York, Cochrane Database of Systematic Reviews, Cochrane Skin Group, Centre of Evidence based dermatology de la
Introduction

Hidradenitis suppurativa (HS) is a chronic, debilitating inflammatory disease of hair follicles and their associated sebaceous glands. HS usually appears after puberty. Underlying the condition is immune dysregulation in a genetically predisposed individual. The general population prevalence, which ranges from 0.1% to 1%, is higher in the second and third decades of life and in women. Smoking, obesity, hormonal imbalance, and stress from friction or shaving can trigger or aggravate HS.

Nodules, abscesses, suppurative fistulous tracts, and scarring in skin folds (mainly the armpits, groin, and anogenital regions) are the most common presentations. The main symptoms are pain, burning or a local sensation of heat; pruritus; and hyperhidrosis. These manifestations have a negative impact on quality of life.

The management of HS is complex and requires a multidisciplinary approach. Light-based treatments have been used experimentally in recent years. Photodynamic therapy (PDT) involves applying a photosensitizer that produces reactive oxygen species in a process that leads to cellular destruction. The hypothesized benefit of PDT in HS is based on a direct cytotoxic effect on biofilm bacteria and sebaceous glands as well as on immunomodulation. When a photosensitizer is applied topically to HS lesions, accumulation occurs more easily than in normal skin because openings and fistulas facilitate penetration. Lesions improve with light activation. Light at a wavelength of 630 nm is sufficient for activating 5-aminolevulinic acid (ALA) and methylene blue (MB), which are 2 of the photosensitizers used. Topical PDT has advantages that make it an attractive alternative therapy for treating multiple lesions simultaneously; it is minimally invasive, has few adverse effects, and is well tolerated.

Intense pulsed light (IPL) therapy uses a broad spectrum, high energy, noncoherent light. The underlying principle is photon absorption by endogen or exogen chromophores. The transfer of energy to target cells (in HA, the occluded hair follicle unit) generates heat, destroying the lesion in a process termed selective photothermolysis. IPL also has an antimicrobial effect due to the activation of bacterial porphyrins, which generates reactive oxygen species and leads to cell death.

Nd:YAG, carbon dioxide (CO₂), alexandrite, and diode laser therapies have also been used to treat HS. The aim of these treatments is to reduce the number of hair follicles in areas where HS lesions tend to develop.

This systematic review aimed to update our understanding of the efficacy and safety of the various modalities of light-based therapy applied in HS. We considered both conventional PDT and intralesional and laser treatments. However, we did not compare them, given that their mechanisms of action differ and publications are few.

Material and Methods

Literature Search Strategy

We searched for articles on light-based therapies used alone or with a photosensitizer (PDT) to treat HS. Articles had to be published between August 2015 and March 1, 2019. Additional limiters were set to select studies in humans that were published in either Spanish or English. We started the search with August 2015 because a systematic review in the Cochrane Library was updated at that time. Our intention was to update that review with the results of more recent studies.

We also searched backwards from the reference lists to identify any cited articles meeting our inclusion criteria.

The following databases were used: MEDLINE (through PubMed), EMBASE, the Centre of Reviews and Dissemination (University of York), the Cochrane Library (in the Cochrane Database of Systematic Reviews), the Cochrane Skin Group, the Centre of Evidence Based Dermatology (University of Nottingham), and TESEO (the Andalusian database of PhD theses). The following trial registries were also consulted: ClinicalTrials.gov, reec.aemps.es, and Clinicaltrialregister.eu.

Finally, the PROSPERO register was searched for systematic reviews on HS. We specified reviews that included light-based therapies.

Search terms were chosen from the list of Medical Subject Headings (English) and its equivalent in Spanish (Descriptores en Ciencias de la Salud), as follows: photocoagulation, photodynamic therapy, hidradenitis suppurativa, suppurative hidradenitis, light, lasers, laser therapy, intense pulsed light therapy.

Article inclusion criteria were as follows:

- Type of study: randomized controlled clinical trials (RCTs), systematic reviews, observational studies with a control group, and observational studies without a control group (case series)
- Population: adults with HS regardless of sex, ethnicity, comorbidity, or prior treatment
- Limiter: inclusion of patients whose HS was treated with PDT (using any type of laser or other light source)
- Limiter: publication in Spanish or English
Article exclusion criteria were as follows:

- Publication outside the time frame
- Studies not using accepted, validated HS evaluation tools (eg, the Hidradenitis Suppurativa Clinical Response criterion, the modified Sartorius score, and/or the Physician Global Assessment [PGA] of HS)
- Case series with fewer than 5 patients
- Editorials and narrative reviews

Data Management, Extraction and Synthesis, and Analysis of Research Design Quality

Search results were downloaded with Mendeley reference management software, with titles and abstracts in separate fields. All duplicate, discarded, and selected references were recorded (Fig. 1). The literature searches were not blinded to authors’ names or institution or the publishing journal.

The scale of Jadad et al\textsuperscript{13} was used to evaluate RCTs. Critical analysis was based on the CONSORT guidelines (Consolidated Standards for Reporting Clinical Trials).\textsuperscript{14} The tool of the Basque Office for Health Technology Assessment (OSTeba, its Spanish acronym)\textsuperscript{15} was used to assess the quality of evidence afforded by several types of studies and build a table synthesizing the results.

Results

Included and Excluded Studies

Of the 199 studies found, we excluded 164 after removing duplicates and assessing the titles and abstracts. We evaluated 35 full texts, excluding 24 that did not meet the inclusion criteria. Some did not have 5 patients,\textsuperscript{9,12,16–27} (See Appendix B, supplementary material.) Because few clinical trials and systematic reviews were found, we included case series even though their evaluation of efficacy and effectiveness is limited.

Thus, we evaluated 6 case series (5 prospective and 1 retrospective). The evidence level was low in 4 of the series and moderate in 2 of them.

Most studies were carried out in Europe (Spain, the United Kingdom, France, and Italy), the United States, and Egypt. The remaining inclusions were 2 moderate-quality RCTs and 3 high-quality systematic reviews. The reviews included 4 trials and 5 case series on light-based treatments and are analyzed in depth in the present systematic review: Fadel and Tawfik,\textsuperscript{38} Highton et al,\textsuperscript{11} Tierney et al,\textsuperscript{29} Calzavara-Pinton et al,\textsuperscript{40} Schweiger et al,\textsuperscript{41} Sotiriou et al,\textsuperscript{42} Madan et al,\textsuperscript{44} and Xu et al.\textsuperscript{35}

Tables 1–3 summarize the studies’ periods of follow-up, numbers of patients and losses, population characteristics and interventions. One relevant study\textsuperscript{37} was found in a backward citation search of references.

Sample Size

The number of participants in the included studies ranged widely. The maximum was 38\textsuperscript{46} and the minimum was 5,\textsuperscript{2,42} for a total of 248 patients (mean, 15.5 patients).

Participants

All the studies included men and women older than 18 years with a clinical diagnosis of HS.

One study included only Hurley stage 1 patients (Zerbinati et al\textsuperscript{48} and 1 included only Hurley stage 2 patients (Mahmoud et al\textsuperscript{44}). Two studies included both Hurley 1 and 2 stages (Abdel Azim et al\textsuperscript{48} and Fabbrocini et al\textsuperscript{48}). Six studies required moderately severe HS (Hurley stages 2 or 3) at baseline (Andino Navarrete et al,\textsuperscript{2} Agut-Busquet et al,\textsuperscript{1} Highton et al,\textsuperscript{11} Tierney et al,\textsuperscript{29} Xu et al,\textsuperscript{35} and Sotiriou et al\textsuperscript{42}). One study included any stage of severity (stages 1, 2, or 3) (Suárez Valladares et al\textsuperscript{50}). Finally, 5 studies did not specify stage (Valladares-Narganes et al,\textsuperscript{51} Fadel and Tawfik,\textsuperscript{38} Calzavara-Pinton et al,\textsuperscript{40} Madan et al,\textsuperscript{44} and Schweiger et al\textsuperscript{41}).

Study Designs

We included 3 systematic reviews for this systematic update (Ingram et al,\textsuperscript{3} John et al,\textsuperscript{52} and Robert et al\textsuperscript{53}) and 2 clinical trials (Fadel and Tawfik\textsuperscript{38} and Abdel Azim et al\textsuperscript{48}). The remaining studies were case series.

The systematic review of Ingram et al\textsuperscript{3} included 3 RCTs comparing topical PDT, IPL and Nd:YAG laser therapy.\textsuperscript{11,38,39} Fadel and Tawfik\textsuperscript{38} used an active comparator in the control group. Controls were untreated in Highton et al,\textsuperscript{11} whereas Tierney et al\textsuperscript{29} applied 1% clindamycin cream in the control group. The systematic review of John et al\textsuperscript{52} included 22 studies. Three provided high-quality evidence (and were also included by Ingram et al). The only additional metric that met our criteria was that of Xu et al,\textsuperscript{35} which assessed Nd:YAG laser treatment. The most up-to-date systematic review was by Robert et al,\textsuperscript{53} who included 64 articles about the nonsurgical treatment of HS (with medications or light therapies). Studies of light-based treatments that were not included in the aforementioned reviews were those of Calzavara-Pinton et al\textsuperscript{40} (PDT with methyl aminolevulinate [MAL]) and Schweiger et al\textsuperscript{41} and Sotiriou et al\textsuperscript{42} (PDT with ALA). This third systematic review also included two case series of patients treated with Nd:YAG laser (Mahmoud et al\textsuperscript{44}) and CO\textsubscript{2} laser (Madan et al\textsuperscript{44}).

Only 2 RCTs were retrieved. One was by Fadel and Tawfik,\textsuperscript{38} which was found by backwards searching of citations as described above. The other was by Abdel Azim et al,\textsuperscript{48} which evaluated a combined treatment with CO\textsubscript{2} laser followed by Nd:YAG laser.

One of the case series we included studied the use of PDT with 20% ALA as the photosensitizer and 635-nm laser (Andino Navarrete et al\textsuperscript{2}). Three studies analyzed intrale- sional PDT. Two used ALA at concentrations of 5% and 1% and a 630-nm laser light source.\textsuperscript{50,51} The third used MB and a 635-nm light-emitting diode (LED) lamp (Aktilit).\textsuperscript{1}
<table>
<thead>
<tr>
<th>Reference, y</th>
<th>Study Design, Aim and Period</th>
<th>Study Population</th>
<th>Intervention and Follow-up</th>
<th>Results</th>
<th>Conclusions</th>
<th>Comments</th>
<th>Quality of Evidence</th>
</tr>
</thead>
<tbody>
<tr>
<td>Andino Navarrete et al,2 2014</td>
<td>Design: prospective case series Objective: To assess the efficacy (Sartorius, DLQI) and safety of PDT + ALA and 635-nm light treatment of moderate to severe HS</td>
<td>No. of patients: 5 Characteristics: HS type 2 or Hurley stage 3; 4 armpit lesions, bilateral + 1 pubic; 1 man, 4 women; Mean age, 26 (5) y; Mean time since onset, 4 (1) y</td>
<td>20% ALA solution for 1.5 h; light (635 nm, 37 J/cm², 70 mW/cm²) per session Minimum 4 sessions spaced 1–2 wk Follow-up: 4 and 8 wk Losses: 0</td>
<td>Significantly improved severity, DLQI, and VAS scores at 8 wk Mean Sartorius decrease of 35 (5) to 18 (8) points DLQI decrease, 21 points after 4 sessions, sustained at 8 wk VAS pretreatment, 3; decrease (0–1) at 4 and 8 wk, all patients Only adverse effect, burning on irradiation (2 patients)</td>
<td>Treatment with topical 20% ALA and 635-nm light could be effective for refractory HS, decreasing severity and improving QoL.</td>
<td>Small series, limiting external validity and extrapolation</td>
<td>Low</td>
</tr>
<tr>
<td>Fadel and Tawfik,15 2015</td>
<td>Design: single-blind RCT Objectives: To assess the efficacy and safety of MB niosome gel as photosensitizer in IPL treatment of HS Study period: 6 mo (month and year not specified)</td>
<td>No. of patients: 17, intraindividual (contralateral control); 6 exclusions; 11 cases analyzed. Characteristics: 7 women, 4 men; mean age 27.1 y (range, 17–35 y). Lesions: both armpits (4); multiple gluteal (3); groin (2); under breasts (1). No topical or systemic treatment 2 weeks before enrollment.</td>
<td>Intervention side: PDT with topical 0.01% MB gel + IPL (630 nm, 20 ms, 25 J) every 2 wk 2 sessions/mo up to 6 mo Control side: PDT with placebo topical MB-free gel + IPL (630 nm, 20 ms, 25 J/cm²) every 2 wk Follow-up: 1, 3, and 6 mo after treatments Losses after randomization: 0</td>
<td>PDT with topical 0.01% MB gel + IPL was superior to placebo gel; reduction of Sartorius score by 77.3% and 44.1%, respectively. Mean HS-LASI improvement was significant in both groups: active treatment, 77.3% (18.86%); vs placebo gel, 44.1% (28.19%). Similar adverse effects (pain, erythema, hyperpigmentation); no effect of treatment site or disease stage Adverse effects: 0</td>
<td>IPL (630 nm) with this photosensitizer (MB) is effective. MB in niosome formulation enhances dermal penetration. Hair follicle destruction was also attributed to 630-nm light.</td>
<td>Limited by small sample size and short follow-up period. Intraindividual RCTs with more patients and longer follow-up are needed. RCTs with comparators (medical and surgical treatments) are also needed.</td>
<td>Moderate</td>
</tr>
<tr>
<td>Reference, y</td>
<td>Study Design, Aim and Period</td>
<td>Study Population</td>
<td>Intervention and Follow-up</td>
<td>Results</td>
<td>Conclusions</td>
<td>Comments</td>
<td>Quality of Evidence</td>
</tr>
<tr>
<td>--------------</td>
<td>-----------------------------</td>
<td>------------------</td>
<td>---------------------------</td>
<td>---------</td>
<td>-------------</td>
<td>----------</td>
<td>---------------------</td>
</tr>
<tr>
<td>Ingram et al, 2015</td>
<td>Design: systematic review of RCTs</td>
<td>Any person (any sex, age, or ethnicity) with a clinical diagnosis of HS made by a physician and based on a standard definition of the disease</td>
<td>Interventions: More than 40 interventions for HS were included, though evidence was lacking for many. Interventions grouped as pharmacologic, surgical, and other. 3 trials: Fadel and Tawfik, 2015 Intervention 1: PDT with topical 0.01% MG gel + IPL (630 nm, 20 ms, 25 J/cm²) every 2 wk Intervention 2: PDT with placebo gel + IPL (630 nm, 20 ms, 25 J/cm²) every 2 wk, 2 sessions/mo up to 6 mo Highton et al, 2011 randomized sides, 1 untreated control side and 1 treated with IPL, twice weekly for 4 wk (420 nm, 7–10 J/cm² a 50 ms) Tierney et al, 2009 Left and right sides of the same anatomical structure received 1 of the following treatments: - 10% benzoyl peroxide wash and 1% clindamycin gel or lotion (frequency not indicated). - 4 Nd:YAG laser treatments monthly and topical 10% benzoyl peroxide and 1% clindamycin</td>
<td>No. of studies and patients: 12 trials with 615 patients Median, 27 participants; mean duration of treatment, 16 wk. Included studies were done between 1983 and 2015. Effect size: The 3 trials of laser or other light-based treatments were judged to offer a low level of evidence because of lack of precision and adequate blinding. Fadel and Tawfik, 2015 PDT with topical 0.01% MB gel + IPL was superior to placebo MB gel + IPL; Sartorius score fell by 77.3% and 44.1%, respectively Highton et al, 2011 Significant benefit from IPL in 18 patients: mean Sartorius score reduction of 12% immediately after therapy, 10% at 3 months, 10% at 6 months, and 3% at 12 months. No comparator. Patients assessed satisfaction on an unvalidated Likert scale. Tierney et al, 2009 17 patients, 4 Nd:YAG laser treatments at monthly intervals on 1 side of the body in 25 regions with lesions. Significantly improved Sartorius scores in treated armpits. A 65.3% reduction in HS severity at 3 mo overall. By locations: 73.4% groin, 62% armpits, 53.1% under breasts.</td>
<td>Studies of Nd:YAG laser, IPL, and topical PDT treatments were of poor quality because of lack of blinding and absence of placebo comparison.</td>
<td>High</td>
<td></td>
</tr>
</tbody>
</table>
Table 1 (Continued)

<table>
<thead>
<tr>
<th>Reference, y</th>
<th>Study Design, Aim and Period</th>
<th>Study Population</th>
<th>Intervention and Follow-up</th>
<th>Results</th>
<th>Conclusions</th>
<th>Comments</th>
<th>Quality of Evidence</th>
</tr>
</thead>
<tbody>
<tr>
<td>John et al, 2016</td>
<td>Design: systematic review of RCTs and nonrandomized trials, other systematic reviews, case-control cohort studies, case series, and expert opinion</td>
<td>Any individual regardless of sex, age, or ethnicity with a diagnosis of HS treated by any type of laser</td>
<td>Interventions: 47 studies found; 22 analyzed after applying inclusion and exclusion criteria. Two studies provided grade A evidence (Jadad scale) and 1 provided grade B evidence. Laser therapy was assessed in 3 studies: Higher quality evidence (grade A, Jadad) from Highton et al, Tierney et al, both included in the systematic review of Ingram et al, Xu et al provided grade B evidence (Jadad).</td>
<td>No. of studies and patients: 22 studies, 2 with grade A evidence, 1 with grade B, and the rest with grade C (very low). In total, 59 patients were treated in grade A or B studies. The included studies were done between 1987 and 2016. Effect size: grade A evidence assigned to the trials of Highton et al, Tierney et al, as explained in the entry for the inclusions of the systematic review of Ingram et al, Xu et al, 2011, grade B. The percent change in Sartorius score after 2 mo of treatment was 31.6% (P = .001) on average for all lesion sites; 24.4% (P = .008) for armpits and 36.8% for groin (P = .001). But on histology 3 patients still had inflammation, and the percent changes were not clinically significant.</td>
<td>The conclusion was that there was moderate support for the efficacy of long-pulse Nd:YAG laser and IPL in HS and for reducing recurrence by means of hair follicle destruction; and limited evidence for CO2 laser.</td>
<td>Large RCTs, preferably multicenter ones, are needed to standardize assessment techniques and assess efficacy.</td>
<td>High</td>
</tr>
</tbody>
</table>

Period searched: 1987-April 2016
Table 1 (Continued)

<table>
<thead>
<tr>
<th>Reference, y</th>
<th>Study Design, Aim and Period</th>
<th>Study Population</th>
<th>Intervention and Follow-up</th>
<th>Results</th>
<th>Conclusions</th>
<th>Comments</th>
<th>Quality of Evidence</th>
</tr>
</thead>
<tbody>
<tr>
<td>Robert et al, 2017</td>
<td>Design: systematic review of RCTs and nonrandomized trials, other systematic reviews, case–control cohort studies, case series, and expert opinion</td>
<td>Included: all original research articles on nonsurgical HS treatments (RCTs, prospective or retrospective observational studies, and case series of at least 4 patients) Excluded: single case studies, narrative reviews, discussions, opinion articles, research letters, and editorials</td>
<td>Interventions: 64 included articles. Evidence level generally low; most were retrospective observational studies. Biological treatments (44%), PDT or other phototherapies (16%), antibiotic therapy (11%), laser (8%), retinoids (6%), and other immunosuppressant therapies. 10 articles on PDT: 4 have already been mentioned elsewhere in our review (Fadel and Tawfiq, 2010; Valladares-Narganes et al., 2008; Andino Navarrete et al., and Highton et al. 2015). After applying our inclusion and exclusion criteria, we evaluated the following: Calzavara-Pinton et al., 2013, treated 6 patients (no Hurley stage reported) with MAL-PDT (red light, 635 nm) every 2 wk for 4 wk. Schweiger et al., 2011, treated 12 patients with ALA-PDT (IPL or blue light), weekly for 4 wk. Sotiriou et al., 2009, treated 5 patients (Hurley stage 2 or higher with 20% ALA and red light (570–670 nm) 3 h later; 4 sessions at 15-d intervals; assessment with VAS, Sartorius score and DLQI). Laser was used in 5 studies. We excluded 2 reports of &lt;5 patients or with nonvalidated assessment tools and Mikkelsen et al., a retrospective series that was not relevant (only evaluating long-term recurrence after CO2 laser). Mahmoud et al., 2010, treated 22 patients (Hurley stage 2) with 4 sessions of long-pulse Nd:YAG laser monthly for 4 mo; follow-up, 6 mo. Madan et al., 2008, treated 9 medically and surgically refractory cases of HS with CO2 (1 session, follow-up at 12 mo).</td>
<td>No. of studies, patients and effect sizes: Calzavara-Pinton et al., 2013, assessed response by PGA. Response was &gt;75% in 33% of patients, moderate in half, and &gt;50% in 1. Schweiger et al., 2011, saw a Sartorius score reduction of 50.8% at 4 wk and 29.9% at 8 wk. Mean DLQI scores were 17.3 at baseline and 13.1 at 4 wk. Tolerance was better with blue light than IPL. Sotiriou et al., 2009, reported that mean Sartorius scores fell from 18.8 at baseline to 17.2 on treated sides at the first follow-up visit. Mean VAS evaluations of disease activity/pain went from 2.4 to 2.1. DLQI scores fell by 6.4%. Mahmoud et al., 2010, measured the effect of Nd:YAG laser in 22 patients with the Sartorius score, reporting a 72% reduction. Madan et al., 2008, reported the PGA of the effect; 7 out of 9 patients had complete remission and expressed high satisfaction.</td>
<td>No nonsurgical treatment leads to long-term remission. The authors emphasized the need for surgery in refractory and debilitating cases. Low quality of evidence. Heterogeneous methods of assessment, scarcely comparable. Few RCTs; most studies are of retrospective cohorts</td>
<td>High</td>
<td></td>
</tr>
</tbody>
</table>

Abbreviations: ALA, 5-aminolevulenic acid; CO2, carbon dioxide; DLQI, Dermatology Life Quality Index; HS, hidradenitis suppurativa; HS-LASI, HS lesion, area and severity index; IPL, intense pulsed light; MAL, methyl aminolevulinate; MB, methylene blue; Nd:YAG, neodymium and neodymium:yttrium aluminum garnet; PDT, photodynamic therapy; QoL, quality of life; RCT, randomized clinical trial; VAS, visual analog scale.

a Means are shown with the SD in parentheses.

b Bold face indicates articles obtained from systematic reviews in which light-based therapies other than PDT were used.
Table 2. Summary of Articles on Intralesional PDT for HS

<table>
<thead>
<tr>
<th>Reference, Year</th>
<th>Study Design, Aim and Period</th>
<th>Study Population</th>
<th>Intervention and Follow-up</th>
<th>Results on the Intralesional PDT for HS</th>
<th>Conclusions</th>
</tr>
</thead>
<tbody>
<tr>
<td>Valladares-Narganes et al, 2015</td>
<td>Design: prospective case series</td>
<td>No. of patients: 27 (single group)</td>
<td>Characteristics:</td>
<td>Complete: 15, Good: 4, Partial: 3</td>
<td>Intralesional 1% ALA solution (dose, 0.2 mL/cm^3). By cannula insertion into fistulous tracts, or needle injection into the diseased area if cannulation was impossible. The entrance to and exit from the fistula was covered for an incubation period of 3 h. Light was transmitted postprocedure through a 1-mm needle. Erythema and slight swelling was observed. If response was suboptimal or new lesions appeared nearby, an additional session was given. Follow-up: 1, 3, and 6 mo. Losses: 1.</td>
</tr>
<tr>
<td>Reference, y</td>
<td>Study Design, Aim and Period</td>
<td>Study Population</td>
<td>Intervention and Follow-up</td>
<td>Results</td>
<td>Conclusions</td>
</tr>
<tr>
<td>-------------</td>
<td>-----------------------------</td>
<td>------------------</td>
<td>---------------------------</td>
<td>---------</td>
<td>-------------</td>
</tr>
</tbody>
</table>
| Agut-Busquet et al, 2016 | Design: respective case series  
Objective: To describe the experience with 7 patients with HS treated with PDT using intralesional MB and light (635 nm)  
Study period: 8 mo | No. of patients: 7  
Characteristics: HS clinical type 2, Hurley stage 3, at least 1 active zone | Intralesional 1% MB solution injected with or without ultrasound guidance.  
After incubation (15 min), irradiation with a 635-nm LED light (37 J/cm²)  
1-2 sessions, intervals of 15 d.  
Follow-up: 1, 2, 4, and 6 mo  
Losses: 1 | Hurley stage-2 patients responded better than stage-3 patients (99% vs 87% improvement); best results in the groin. DQLI improvement in 6 patients: 78% (1), 80% (1), 90% (2), and 99% (2). Evaluation, Sartorius score and PGA: 78% (1 patient), 80% (1), 90% (2), 99% (2). Good response (86% improvement) to antibiotic in only 1 patient.  
Adverse effects: mild in 6 cases (86%); serious in 1 patient (cellulitis at treatment site, attributed to patient’s manipulation of the area after therapy) | Intralesional PDT with MB gives good results in HS but is more effective in Hurley stage 2 than stage 3. RCTs are necessary to improve the quality of evidence. | Few patients, making extrapolation to the general population (external validation) difficult. | Low |
<table>
<thead>
<tr>
<th>Reference, y</th>
<th>Study Design, Aim and Period</th>
<th>Study Population</th>
<th>Intervention and Follow-up</th>
<th>Results</th>
<th>Conclusions</th>
<th>Comments</th>
<th>Quality of evidence</th>
</tr>
</thead>
<tbody>
<tr>
<td>Suárez Valladares et al, 2017</td>
<td><strong>Design:</strong> prospective case series</td>
<td><strong>No. of patients:</strong> 38</td>
<td>Single session regardless of site, but the median energy used was greater in the armpits. Complete remission in 76.3%, mean disease-free period of 168 wk. New lesions at untreated sites were observed in 9 patients (23.7%); 6 of them had complete remission. Recurrence or no remission after treatment in 9 patients, in whom the percentages of obesity (33.3% vs 58.6%) and smoking (66.7% vs 96.6%) were lower but disease severity was greater (44.4% vs 31%), modified Sartorius score was higher (36 vs 22) and DLQI poorer (16 vs 10) than in those with a good response to PDT.</td>
<td><strong>Conclusions</strong></td>
<td><strong>Comments</strong></td>
<td><strong>Quality of evidence</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Objective:</strong> To evaluate the efficacy of intralesional PDT for the local management of HS in the short and medium term in different sites</td>
<td><strong>Study period:</strong> March 2011–November 2015</td>
<td>Intralesional PDT might offer a new alternative treatment for HS lesions, alone or in combination; a high rate of complete remission was achieved and was long-lasting. No complications observed. Rapid recovery after treatment, with the possibility of repeating sessions.</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Study Design, Aim and Period</strong></td>
<td><strong>No. of patients:</strong> 38</td>
<td>After local anesthesia, 5% ALA gel was injected through a cannula to fill the fistulous tracts. Thus, all walls of fistulous tracts were treated regardless of depth. A lyophilized 1% solution was injected into nodules. Incubation under occlusion for 2 h before irradiation. Irradiation (1.2 W; fluence, 180 J/cm²) with an intralesional 630-nm laser through a 400-mm fiberoptic probe inserted through a needle.</td>
<td><strong>Results</strong></td>
<td><strong>Conclusions</strong></td>
<td><strong>Comments</strong></td>
<td><strong>Quality of evidence</strong></td>
</tr>
<tr>
<td></td>
<td><strong>Characteristics:</strong></td>
<td><strong>Follow-up visits every 5–7 wk</strong></td>
<td><strong>Follow-up:</strong> 26.1 (21.7–68.57) mo</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Sex: 20 women, 18 men</td>
<td><strong>Losses:</strong> 0</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Age: 30-44 y</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Weight: 67.25–90 kg</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>BMI: 26.87 (4.89)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>BMI &gt;27: 20</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Smokers: 34</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Prior treatments: 2, none; 1, topical; 23, oral antibiotics; 2, oral retinoids; 1, biologic; 9, surgery.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Hurley stages: 1, 4 patients; 2, 21 patients; 3, 13 patients.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Direct measures of severity: Hurley, baseline/total HSS, and DLQI indicated high disease activity.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Abbreviations:** BMI, body mass index; DLQI, Dermatology Life Quality Index; E, energy; HS, hidradenitis suppurativa; HSS, hidradenitis severity score; IR, irradiation; MB, methylene blue; PDT, photodynamic therapy; PGA, Physician’s Global Assessment; RCT, randomized clinical trial; VAS, visual analog scale.
<table>
<thead>
<tr>
<th>Reference, y</th>
<th>Study Design and Period</th>
<th>Population</th>
<th>Intervention and Follow-up</th>
<th>Results</th>
<th>Conclusions</th>
</tr>
</thead>
<tbody>
<tr>
<td>Zerbinati et al., 2017</td>
<td>prospective case series</td>
<td>Hurley stage 1</td>
<td>12 HS patients</td>
<td>Mean age 39.5 y (range, 24-50 y), bilateral disease</td>
<td>Nd:YAG laser (1064 nm) in 300-600-μm polycarbonate-coated glass optical fiber; fluence, 300 J/cm². Different fiber diameters were used according to lesion size and site. Pulse energy, 150-350 mJ. 3 laser sessions (1 every 2 mo). Follow-up, 12 mo.</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Reference, y</td>
<td>Study Design, Aim and Period</td>
<td>Study Population</td>
<td>Intervention and Follow-up</td>
<td>Results</td>
<td>Conclusions</td>
</tr>
<tr>
<td>-------------</td>
<td>-----------------------------</td>
<td>-----------------</td>
<td>---------------------------</td>
<td>---------</td>
<td>-------------</td>
</tr>
<tr>
<td>Nd:YAG and CO&lt;sub&gt;2&lt;/sub&gt; Abdel Azim et al, 2018</td>
<td>Design: RCT, intraindividual, blinded Objectives: To study the safety and efficacy of combined treatment with fractional CO&lt;sub&gt;2&lt;/sub&gt; and long-pulse (1064 nm) Nd:YAG laser therapy for treating HS. Study period: January–December 2017</td>
<td>No. of patients: 20 (30 enrolled, 10 excluded) Characteristics: patients &gt;18 y with bilateral Hurley stage 1 or 2 lesions</td>
<td>Intervention: 4 laser sessions at 2-wk intervals. Intervention-side treatment was combined fractional CO&lt;sub&gt;2&lt;/sub&gt; followed by long-pulse (1064 nm) Nd:YAG laser in the same session. Control: contralateral side, long-pulse (1064 nm) Nd:YAG laser only Follow-up: 3 mo after last session Losses after randomization: 5 during follow-up to assess sustained response</td>
<td>Significant improvement and greater patient satisfaction for the combined treatment over the control treatment (P = .011 and .048, respectively). PGA evaluation of response to treatment showed absence of recurrence in 55% of the intervention sides (combined treatment) vs 35% on the control sides. Histology of the skin 2 wk after the last session revealed a scant perifollicular lymphohistiocytic infiltrate on the combined-treatment side. Less decrease in the infiltrate and in dermal edema on the Nd:YAG-only side. No adverse effects other than erythema, which resolved spontaneously by 48 h. Adverse effects: 1 patient</td>
<td>Combined fractional CO&lt;sub&gt;2&lt;/sub&gt; and long-pulse (1064 nm) Nd:YAG laser therapy achieves greater improvement and patient satisfaction and lower recurrence rates in comparison with Nd:YAG therapy alone for HS in Hurley stages 1 and 2. Combined therapy could achieve better results in patients with low PGA scores who are not obese and have not undergone prior surgery at the site of a lesion.</td>
</tr>
<tr>
<td>Reference, y Study Design, Aim and Period</td>
<td>Study Population</td>
<td>Intervention and Follow-up</td>
<td>Results</td>
<td>Conclusions</td>
<td>Comments</td>
</tr>
<tr>
<td>------------------------------------------</td>
<td>------------------</td>
<td>----------------------------</td>
<td>---------</td>
<td>-------------</td>
<td>----------</td>
</tr>
<tr>
<td>Intralesional diode laser Fabbrocini et al, 2018</td>
<td>No. of patients: 20 Characteristics: patients with Hurley stage 1 or 2 HS, mild-moderate according to PGA</td>
<td>Diode laser (1064 nm) in 300–600 nm polycarbonate-coated glass optical fiber. Fluence, 250 J/cm², fiber diameters varied according to type of lesion and site. Pulse energy, 150–350 ms; selected potency, 6–8–10 W. A 30-gauge needle was used to inject an anesthetic solution (1 mL/cm²) until tumescence. On the day of treatments, all patients started azithromycin (500 mg/d for 3 d).</td>
<td>Each patient underwent 4 laser sessions at 2-wk intervals. Significant reduction (31%) in the Sartorius score from 28.55 (13.04) to 19.75 (12.29) after 4 sessions (P&lt;.05). No patient worsened. Quality of life improved notably along with clinical improvement (reduction in DLQI scores (P=.0307).</td>
<td>Intralesional 1064-nm diode laser treatment may be a good alternative for patients with moderate, localized HS, given it is minimally invasive and does not have significant complications. Recovery is rapid.</td>
<td>Few patients, low quality of evidence</td>
</tr>
</tbody>
</table>

Abbreviations: CO₂, carbon dioxide; DLQI, Dermatology Life Quality Index; HS, hidradenitis suppurativa; Nd:YAG, neodymium-doped yttrium aluminum garnet; PGA, Physician’s Global Assessment; RCT, randomized clinical trial.  
* Means are shown with the SD in parentheses.
Zerbinati et al.\textsuperscript{47} analyzed case series in which Nd:YAG laser was used, and Fabbrocini et al.\textsuperscript{48} evaluated the efficacy of diode laser irradiation in mild to moderate HS.

Outcomes Measures

The included studies assessed outcomes in somewhat different ways. Most used the Sartorius score of 2003,\textsuperscript{1,2,11,38,39,41-43,45,47,49} but 2 studies used the modified version of this score.\textsuperscript{50,51} Five (Agut-Busquet et al.,\textsuperscript{1} Abdel Azim et al.,\textsuperscript{48} Calzavara-Pinton et al.,\textsuperscript{49} Fabbrocini et al.,\textsuperscript{49} and Madan et al.)\textsuperscript{61} used the PGA.

Six evaluated changes in quality of life with the Dermatology Life Quality Index (DLQI) published by Finlay in 1994.\textsuperscript{1,2,41,42,49,50} General satisfaction was evaluated by Highton et al.\textsuperscript{11} with an unvalidated Likert scale and by Madan et al.\textsuperscript{61} with a score of 0 (very unsatisfied) to 10 (very satisfied).

Two studies assessed pain during and after treatment using a visual analog scale (VAS).\textsuperscript{2,51}

Four studies provided information about adverse effects,\textsuperscript{1,2,51} although Highton et al.\textsuperscript{11} only reported such effects if treatment had to be interrupted.

Finally, 5 studies reported recurrence rates. Agut-Busquet et al.\textsuperscript{1} emphasized recurrence, explaining each case. Suárez Valladares et al.\textsuperscript{62} reported recurrence in 9 patients. Highton et al.\textsuperscript{11} found that HS tended to recur 12 months after treatment. Recurrence 3 and 12 months after treatment was assessed by Abdel Azim et al.\textsuperscript{61} and Madan et al.,\textsuperscript{61} respectively.

Outcomes Obtained With Light-Based Therapies

Tables 1–3 summarize the research designs used and quality of evidence obtained by researchers studying the use of conventional PDT, intraliesional PDT, and laser treatments. As explained above, the 3 systematic reviews we consulted included patients treated with both PDT and laser therapy. Therefore, to avoid repetition, one table (Table 1) presents the studies that applied laser treatments and IPL in bold face type.

PDT

Andino Navarrete et al.\textsuperscript{61} treated 5 patients with a 20% ALA solution for 1.5 h and then irradiated the area with a 635-nm LED lamp at a fluence of 37 J/cm\(^2\) and intensity of
70 mW/cm² per session. The patients experienced improvements (Sartorius score, DLQI, and VAS) that was maintained at 8 weeks, although the differences were not statistically significant.

Fadel and Tawfi38 used PDT with a 0.01% MB gel (formulation in liposomes with surfactants to increase penetration) and compared it to placebo (MB-free) gel. The area was irradiated with IPL (630 nm) for 20 ms at a fluence of 25 J/cm². The participants were authorized to receive treatment at every affected area of the body (armpits, buttocks, groin, and under the breasts). Results showed a Sartorius score reduction of 77.3% (liposome MB gel formulation) and 44.1% (MB-free placebo) (P < .01). The authors concluded that PDT with MB in this formulation is superior to irradiation after MB-free gel.38

Calzavara-Pinton et al40 studied patients with various diseases treated with MAL-PDT; 6 patients with HS were among them. The authors irradiated with red light (635 nm) every 2 weeks for 4 weeks and reported a PGA assessment of more than 75% in 33% of the cases, moderate improvement in half, and a poor response in 1 patient.

Schweiger et al41 described 12 patients treated with ALA-PDT with blue light and IPL weekly for 4 weeks. Four weeks after treatment they observed a reduction in the Sartorius score of 50.8%. At 8 weeks the reduction was 29.9%. The DLQI score fell from 17.3 to 13.1. Blue light was tolerated better than IPL.

Finally, Sotiriou et al42 applied a 20% ALA formulation in 5 sessions in 5 patients with Hurley stage 2 or higher HS. The mean Sartorius score decreased from 18.8% to 17.2%, and DLQI impact fell 6.4% on average. These results are summarized in Table 1.

Intralesional PDT

Valladares-Narganes et al50 administered 1% ALA (0.2 mL/cm²) into lesions followed by light exposure, as noted above, in a series of 27 patients with 1 to 3 lesions each. After 26.21 months (range, 21.07–68.57 months), responses were complete in 10 patients (37%), moderate in 11 (41%), and partial in 5 (19%). The authors saw the best results in armpit lesions (Table 2).

Agut-Busquet et al33 injected a 1% MB solution into lesions under ultrasound guidance in 7 patients. After incubation (15 minutes), the lesions were irradiated with an LED lamp (Aktorite, 635 nm, 37 J/cm²). After 6 months the global assessment of response was 78% in 1 patient, 80% in 1, 90% in 2, and 99% in 2. Patients with Hurley stage 2 HS responded better (99%) than those with Hurley stage 3 (87%), and the best results were observed in groin lesions. DLQI improved significantly for 6 patients, coinciding with excellent response to treatment. Mild adverse effects (swelling or erythema) were observed in 6 patients (86%), but they resolved within a week (Table 2).

Suárez Valladares et al50 injected a 5% ALA gel into lesions through a cannula placed along the sinus tract in 38 patients. After incubation under opaque occlusion for 2 hours, intralesional laser irradiation (630 nm, 1.2 W; fluence, 180 J/cm²) was applied with a fiberoptic probe (400 nm). All regions treated improved according to modified Sartorius scale results. There were 53 complete responses, 7 good responses, and 4 partial responses. However, the differences were not statistically significant (Table 2).

Nd:YAG Laser Treatment

Tierney et al39 compared Nd:YAG treatments with 10% benzoyl peroxide and daily application of 1% clindamycin versus application of the topical antibiotic alone. Seventeen patients were enrolled and 4 laser sessions were given at intervals of 1 month (Table 1). The reduction in severity according to modified Sartorius assessment was 65.3% at 3 months on average over all regions (73.4% in the groin, 62% in the armpits, and 53.1% under the breasts). Improvement was significant in laser-treated patients, but not in the control group (topical clindamycin only) (P < .02).

Xu et al43 published a prospective, controlled histopathologic study in 19 patients with Hurley stage 2 HS. The patients were treated in 2 monthly sessions of Nd:YAG laser therapy (1064 nm). The percent response to treatment on the Sartorius score after 2 months was 31.6% (P = .001). Greater improvement was recorded in groin lesions (Table 1).

Zerinati et al47 observed a mean improvement of 85.3% in the Sartorius score with Nd:YAG treatment of very early Hurley stage 1 HS in 12 patients (Table 3). In a similar study, but with 22 patients with more severe HS (Hurley stage 2), Mahmoud et al45 evaluated the response at 6 months to 4 sessions of a 1 long-pulse Nd:YAG treatment per month for 4 months. They also observed a decrease in the Sartorius score (−72%) (Table 1).

Other Types of Laser Treatment

An RCT of CO₂ laser treatment was carried out by Abdel Azim et al48 in 20 patients over the age of 18 years who had Hurley stage 1 or 2 HS. The aim was to assess the safety and efficacy of combining fractional CO₂ irradiation with long-pulse Nd:YAG laser irradiation (1064 nm) in 4 sessions separated by 2 weeks. On the intervention side the patients received fractional CO₂ laser treatment followed by long-pulse Nd:YAG laser (1064 nm) in the same session. On the control side, only the Nd:YAG treatment was used. The authors concluded that improvement and satisfaction were greater with the combined treatment of early (Hurley stage 1 and 2) disease and that the recurrence rate was lower (Table 3).

Of 9 patients with medically and surgically refractory HS who received CO₂ laser treatments from Madan et al,44 7 had achieved complete remission at 12 months. Satisfaction was high (Table 1).

Finally, Fabbrocini et al49 used laser diode light in a group with Hurley stage 1 or 2 HS and mild to moderate disease according to PGA. The patients received 4 sessions spaced every 2 weeks. A significant reduction of 31% was seen in the Sartorius scores, which changed from 28.55 (SD, 13.04) to 19.75 (SD, 12.29) (P < .05). The authors also reported a direct association between improvement and better quality of life (Table 3).
Very few studies have been published on other types of lasers, but all of them report promising results. The combination of CO2 and Nd:YAG lasers obtained better results than Nd:YAG irradiation alone and patient satisfaction was higher. Madan et al. showed that CO2 laser therapy and marsupialization also led to high rates of complete remission in spite of adverse effects, such as hypertrophic scarring.

We found a single study of diode laser therapy for HS that was considered mild to moderate according to the PGA. The authors reported clinical and quality-of-life improvement after therapy.

In summary, the evidence supporting the use of light-based therapies for HS is limited. There are 2 major groupings of these therapies according to whether a photosensitizer is used or not. In 1 group, for which only a low-moderate level of evidence is available, the authors applied Nd:YAG laser, CO2 laser, or IPL. In the other, for which the quality of evidence is also low-moderate, PDT (with photosensitizer) was used. Thus, all the treatments reviewed used light but they are not comparable: different techniques have different mechanisms of action. However, results for individual treatments do seem to suggest that approaches that offer greater penetration — whether by means of intralesional application or lasers — lead to better results.

RCTs are necessary to confirm the efficacy of these treatments. We also need to see standardized research protocols applying the design that is most appropriate for providing stronger evidence for the efficacy and safety of each technique.

Authorship

T. Gracia Cazaña and L.V. Berdel García contributed equally to this article.

Conflicts of interest

The authors declare that they have no conflicts of interest.

Acknowledgments

We thank Ms Visitación Ortega Riba and Ms Montserrat Salas Valera for their help with the systematic literature review and downloading of articles.

We are also grateful to the Government of the Spanish Autonomous Community of Aragon for their recognition of our research group (reference number B18,17D).

Appendix A. Supplementary data

Supplementary material related to this article can be found, in the online version, at doi:https://doi.org/10.1016/j.adengl.2019.04.019.

References

1. Agut-Busquet E, Romani J, Gilaberte Y, Garcia-Malinis A, Ribera-Pibernat M, Luelmo J. Photodynamic therapy with intralesional methylene blue and a 635 nm light-emitting diode lamp in

IPL

Highton et al. enrolled 18 patients in an RCT comparing active and control treatments on contralateral sides. The active treatment was IPL (50 ms, 420 nm, fluence of 7–10 J/cm²). They observed a mean reduction in the Sartorius score of 12% immediately after therapy, 10% at 3 to 6 months, and 3% at 12 months. The difference between the treated and control sides was significant (P < .01). Patient satisfaction was high. Response was complete in 1 case, excellent in 2 cases, good in 10, and moderately good in 4. Fifteen did not experience significant changes on the control side: 1 patient reported slight improvement and another experienced slight worsening. The treatment was applied once a week for 4 weeks. Follow-up was 12 months (Table 1).

Discussion

Considering the limited evidence available for light-based treatments for HS, it is difficult to draw conclusions about the efficacy of either intralosal versus topical approaches, or IPL or Nd:YAG laser. Variation in study designs makes comparison difficult.

We identified 3 photosensitizers being used in PDT: ALA, MAL, and MB. All of them were applied at different concentrations from 1% to 20% for ALA, 16% for MAL, and 0.01% to 1% for MB. Which concentration leads to a better response rate is difficult to establish because evaluation methods differ. Moreover, the type of light used to irradiate lesions also varies, as some groups use LED lamps, while others apply external or intralosomal laser and still others use IPL. The possibility of treating deep HS lesions is an important factor in efficacy, yet these light sources have stark differences in penetration. The light doses also differ, although the wavelength applied is similar at 630 or 635 nm.

The studies also treated lesions at different sites, for different durations and numbers of sessions (from 1 to 12). The main difference in technique, however was between the use of topical versus intralosomal application of both the photosensitizer (ALA, MAL, or MB) and the light source (LED, laser, or IPL).

We found that intralosomal treatment approaches also differed between authors. Suárez Valladares et al. and Valladares-Narganes et al. used 630-nm diode lasers and ALA at different concentrations. They assessed response with the modified Sartorius score, finding that response was better with a 5% ALA gel and a 400-nm diode laser (1.2 W and 180 J/cm²). Agut-Busquet et al., on the other hand, used a 1% MB formulation and a 635-nm LED with a fluence of 37 J/cm². They assessed efficacy with the DQLI and the Sartorius score, reporting responses that varied from 99% for cases involving Hurley stage 1 to 87% in Hurley stage 3.

The single study of IPL we found reported that statistically significant improvement was maintained for 12 months and that the risk of complications was low. The RCT of Nd:YAG laser treatment by Tierney et al. demonstrated efficacy. Later case series describing this treatment have reported reduction in the number of exacerbations and in severity. Efficacy has been reported to be greater in the groin.


40. Calzavara-Pinton PG, Rossi MT, Aronson E, Sala R, Italian Group For Photodynamic Therapy. A retrospective analysis


